Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study

References

• Saleem MA. Molecular stratification of idiopathic nephrotic syndrome. Nat Rev Nephrol. 2019;15(12):1–8. doi: 10.1038/s41581-019-0217-5.
   PubMed Web of Science ®Google Scholar
• Larkins N, Kim S, Craig J, et al. Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children. Arch Dis Child. 2016;101(4):404–408. doi: 10.1136/archdischild-2015-308924.
   PubMed Web of Science ®Google Scholar
• Saito T. [Refractory nephrotic syndrome]. Nihon Rinsho. 2004;62(10):1794–1799.
   PubMedGoogle Scholar
• Shi B, Zhang RR, Liang Y, et al. Efficacy of traditional Chinese medicine regimen jian Pi Qu shi formula for refractory patients with idiopathic membranous nephropathy: a retrospective Case-Series study. Evid Based Complement Alternat Med. 2018;2018:5854710. doi: 10.1155/2018/5854710.
   PubMed Web of Science ®Google Scholar
• Colucci M, Corpetti G, Emma F, et al. Immunology of idiopathic nephrotic syndrome. Pediatr Nephrol. 2018;33(4):573–584. doi: 10.1007/s00467-017-3677-5.
   PubMed Web of Science ®Google Scholar
• Wang X, Cui Z, Zhang YM, et al. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort. Nephrol Dial Transplant. 2018;33(9):1558–1563. doi: 10.1093/ndt/gfx295.
   PubMed Web of Science ®Google Scholar
• Chauhan K, Mehta AA. Rituximab in kidney disease and transplant. Animal Model Exp Med. 2019;2(2):76–82. doi: 10.1002/ame2.12064.
   PubMedGoogle Scholar
• Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. 2017;28(1):348–358. doi: 10.1681/ASN.2016040449.
   PubMed Web of Science ®Google Scholar
• Ahn W, Bomback AS. Approach to diagnosis and management of primary glomerular diseases due to podocytopathies in adults: core curriculum 2020. Am J Kidney Dis. 2020;75(6):955–964. doi: 10.1053/j.ajkd.2019.12.019.
   PubMed Web of Science ®Google Scholar
• Waldman M, Beck LJ, Braun M, et al. Membranous nephropathy: pilot study of a novel regimen combining cyclosporine and rituximab. Kidney Int Rep. 2016;1(2):73–84. doi: 10.1016/j.ekir.2016.05.002.
   PubMedGoogle Scholar
• Rovin BH, Caster DJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 2): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019;95(2):281–295. doi: 10.1016/j.kint.2018.11.008.
   PubMed Web of Science ®Google Scholar
• Cortazar FB, Rosenthal J, Laliberte K, et al. Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome. Clin Kidney J. 2019;12(2):224–231. doi: 10.1093/ckj/sfy067.
   PubMed Web of Science ®Google Scholar
• Lee JM, Kronbichler A, Shin JI, et al. Current understandings in treating children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2021;36(4):747–761. doi: 10.1007/s00467-020-04476-9.
   PubMed Web of Science ®Google Scholar
• Sinha R, Banerjee S, Mukherjee A, et al. Early use of rituximab in calcineurin inhibitor-refractory and steroid-resistant nephrotic syndrome. Kidney Int Rep. 2020;5(12):2354–2357. doi: 10.1016/j.ekir.2020.09.021.
   PubMed Web of Science ®Google Scholar
• Liu S, Gui C, Lu Z, et al. The efficacy and safety of rituximab for childhood steroid-dependent nephrotic syndrome: a systematic review and meta-analysis. Front Pediatr. 2021;9:728010. doi: 10.3389/fped.2021.728010.
   PubMed Web of Science ®Google Scholar
• Barmettler S, Ong MS, Farmer JR, et al. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1(7):e184169. doi: 10.1001/jamanetworkopen.2018.4169.
   PubMed Web of Science ®Google Scholar
• KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276.
   PubMed Web of Science ®Google Scholar
• Ronco P, Plaisier E, Debiec H. Advances in membranous nephropathy. J Clin Med. 2021;10(4):607. doi: 10.3390/jcm10040607.
   PubMed Web of Science ®Google Scholar
• Gauckler P, Shin JI, Alberici F, et al. Rituximab in membranous nephropathy. Kidney Int Rep. 2021;6(4):881–893. doi: 10.1016/j.ekir.2020.12.035.
   PubMed Web of Science ®Google Scholar
• Lu W, Gong S, Li J, et al. Efficacy and safety of rituximab in the treatment of membranous nephropathy: a systematic review and meta-analysis. Medicine. 2020;99(16):e19804. doi: 10.1097/MD.0000000000019804.
   PubMed Web of Science ®Google Scholar
• Scolari F, Delbarba E, Santoro D, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial. J Am Soc Nephrol. 2021;32(4):972–982. doi: 10.1681/ASN.2020071091.
   PubMed Web of Science ®Google Scholar
• Iwabuchi Y, Moriyama T, Itabashi M, et al. Rituximab as a therapeutic option for steroid-sensitive minimal change nephrotic syndrome in adults. Contrib Nephrol. 2018;195:12–19. doi: 10.1159/000486930.
   PubMed Web of Science ®Google Scholar
• Kamei K, Ishikura K, Sako M, et al. Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children. Pediatr Nephrol. 2020;35(1):17–24. doi: 10.1007/s00467-018-4166-1.
   PubMed Web of Science ®Google Scholar
• World MJ. Military nephrology: a review of cases 1985-2011. J R Army Med Corps. 2012;158(4):300–304. doi: 10.1136/jramc-158-04-04.
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang L, Wang Y, et al. Rituximab in patients with membranous nephropathy and kidney insufficiency. Front Pharmacol. 2022;13:1002117. doi: 10.3389/fphar.2022.1002117.
   PubMed Web of Science ®Google Scholar
• Hanset N, Esteve E, Plaisier E, et al. Rituximab in patients with phospholipase A2 receptor-associated membranous nephropathy and severe CKD. Kidney Int Rep. 2020;5(3):331–338. doi: 10.1016/j.ekir.2019.12.006.
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Prabakaran R, Priya G, et al. Immunosuppressive therapy in primary membranous nephropathy with compromised renal function. Nephron. 2022;146(2):138–145. doi: 10.1159/000518609.
   PubMed Web of Science ®Google Scholar
• Kato R, Pinsky MR. Personalizing blood pressure management in septic shock. Ann Intensive Care. 2015;5(1):41. doi: 10.1186/s13613-015-0085-5.
   PubMedGoogle Scholar
• Suarez J, Busse LW. New strategies to optimize renal haemodynamics. Curr Opin Crit Care. 2020;26(6):536–542. doi: 10.1097/MCC.0000000000000774.
   PubMed Web of Science ®Google Scholar
• Bellomo R, Wan L, May C. Vasoactive drugs and acute kidney injury. Crit Care Med. 2008;36(4):S179–S86. doi: 10.1097/CCM.0b013e318169167f.
   PubMed Web of Science ®Google Scholar
• LeDoux D, Astiz ME, Carpati CM, et al. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med. 2000;28(8):2729–2732. doi: 10.1097/00003246-200008000-00007.
   PubMed Web of Science ®Google Scholar
• Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest. 1993;103(6):1826–1831. doi: 10.1378/chest.103.6.1826.
   PubMed Web of Science ®Google Scholar
• Redl-Wenzl EM, Armbruster C, Edelmann G, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med. 1993;19(3):151–154. doi: 10.1007/BF01720530.
   PubMed Web of Science ®Google Scholar
• Yang XF, Jia XY, Yu XJ, et al. Rituximab for the treatment of refractory anti-glomerular basement membrane disease. Ren Fail. 2022;44(1):1123–1129. doi: 10.1080/0886022X.2022.2097405.
   PubMed Web of Science ®Google Scholar
• Markóth C, File I, Szász R, et al. Ibrutinib-induced acute kidney injury via interstitial nephritis. Ren Fail. 2021;43(1):335–339. doi: 10.1080/0886022X.2021.1874985.
   PubMed Web of Science ®Google Scholar
• Santos JE, Fiel D, Santos R, et al. Rituximab use in adult glomerulopathies and its rationale. J Bras Nefrol. 2020;42(1):77–93. doi: 10.1590/2175-8239-JBN-2018-0254.
   PubMedGoogle Scholar